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Abstract
Background: Abediterol is a novel, once-daily long-acting β2-agonist in development for the treatment of chronic
obstructive pulmonary disease (COPD) and asthma in combination with an anti-inflammatory agent. This Phase IIa,
randomised, double-blind, crossover study investigated the bronchodilation, safety, tolerability and pharmacokinetics of
abediterol in patients with moderate to severe COPD.
Methods: Seventy patients (aged ≥40 years, Global initiative for chronic Obstructive Lung Disease Stage II/III) were
randomised (1:1:1:1:1:1) to single doses of abediterol 0.625, 2.5, 5 or 10 μg, indacaterol 150 μg or placebo. Spirometry
was performed up to 36 h post-dose. Pharmacokinetics were assessed in a subset of patients (N = 20). Safety and
tolerability were evaluated throughout the study.
Results: Abediterol (all doses) significantly improved change from baseline in trough forced expiratory volume in 1 s
(FEV1) compared with placebo (0.102, 0.203, 0.233 and 0.259 L for abediterol 0.625, 2.5, 5 and 10 μg, respectively;
all p < 0.0001; primary endpoint). Abediterol 2.5, 5 and 10 μg significantly improved trough FEV1 compared with
indacaterol 150 μg (0.092, 0.122 and 0.148 L, respectively; all p < 0.0001). Improvements in bronchodilation were
maintained at all time points post-dose versus placebo (all abediterol doses) and from 15 or 30 min post-dose
versus indacaterol 150 μg with abediterol 2.5, 5 and 10 μg (all p < 0.05). Abediterol had low systemic exposure;
incidence of treatment-emergent adverse events was similar between treatment groups.
Conclusions: All doses of abediterol (0.625–10 μg) provided clinically and statistically significant, dose-dependent
improvements in bronchodilation versus placebo, and abediterol 2.5, 5 and 10 μg gave significant improvements
versus indacaterol. All doses of abediterol were safe and well tolerated in patients with COPD.
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Background
Inhaled bronchodilator medications – anticholinergics
and β2-agonists – are central to the symptomatic treat-
ment of chronic obstructive pulmonary disease (COPD)
[1]. Two classes of long-acting bronchodilators are cur-
rently available: (1) long-acting muscarinic antagonists
(LAMAs), i.e. tiotropium, glycopyrrolate and umeclidi-
nium (all once-daily [QD] administration), and aclidinium
bromide (twice-daily [BID] administration); and (2) long-
acting β2-agonists (LABAs), which include formoterol
BID, salmeterol BID, indacaterol QD and olodaterol QD.
In addition, four LABA/LAMA combinations have re-
cently become available for the management of COPD,
namely QD indacaterol/glycopyrrolate (QVA149), vilan-
terol/umeclidinium, tiotropium/olodaterol and twice-daily
aclidinium/formoterol [2–5].
Long-acting bronchodilators are currently the main-
stay of maintenance therapy for patients with moderate
to severe COPD [1, 6]. However, the addition of inhaled
corticosteroids (ICS) may be of benefit to some patients,
particularly those with a history of exacerbations and
more severe disease, as recommended in the Global ini-
tiative for chronic Obstructive Lung Disease (GOLD)
guidelines [6, 7]. Combination therapies including both a
LABA and an ICS in a single inhaler are more effective
at reducing the frequency of moderate to severe exacer-
bations than either drug administered individually [1, 6].
Abediterol is a new LABA being developed as a com-
bination therapy with an anti-inflammatory agent for the
treatment of both asthma and COPD [1, 8]. As a new
chemical entity, studies of abediterol as monotherapy
have been conducted to establish its clinical efficacy and
safety profile [9–15]. In vitro pre-clinical studies with
human β2-adrenoreceptor over-expressing cells in iso-
lated guinea pig tissues and in vivo animal models have
demonstrated that abediterol displays superior broncho-
dilatory potency and similar or superior selectivity for
β2-adrenoreceptors over β1-adrenoreceptors compared
with formoterol, indacaterol, salmeterol, vilanterol and
olodaterol. In vivo models have also confirmed that abe-
diterol has a duration of action similar or superior to
LABA reference compounds, whilst demonstrating a re-
duced effect on heart rate [9, 16–19]. In early-phase
clinical trials, abediterol was associated with rapid and
sustained improvements in bronchodilation compared
with placebo, and doses ≤10 μg were found to be safe
and well tolerated in healthy subjects and patients with
asthma or COPD, with a safety profile consistent with
that expected for the drug class [12, 14, 15, 20].
Here, we report the results of a Phase IIa single-dose
study designed to investigate the bronchodilation, safety,
tolerability and pharmacokinetics (PK) of four doses of
abediterol (0.625, 2.5, 5 and 10 μg) compared with pla-
cebo and with indacaterol 150 μg in patients with
moderate to severe COPD. In addition to the evaluation
of standard bronchodilation parameters such as forced
expiratory volume in 1 s (FEV1) and forced vital capacity
(FVC), inspiratory capacity (IC) was also investigated as
an indirect measure of hyperinflation, a key aspect of
COPD which causes dyspnoea, limits exercise capacity
and contributes to reduced quality of life [21–23].
Methods
Patients
Male and female patients aged ≥40 years with a smoking
history ≥10 pack-years and moderate to severe clinically
stable COPD were eligible for inclusion in the study. Pa-
tients had post-salbutamol FEV1 ≥30 % and <80 % of the
predicted normal value (based on European Community
for Steel and Coal predicted values) and post-salbutamol
FEV1/FVC ratio <70 %. Exclusion criteria included asthma
(as defined by the Global Initiative for Asthma [24]);
oxygen therapy for ≥15 h/day; respiratory tract infec-
tion or COPD exacerbation within 6 weeks of the
screening visit; hospitalisation for COPD exacerbation
≤3 months before screening; body mass index ≥40 kg/m2;
hypertension (≥160/100 mmHg) or resting heart rate
≥100 bpm at screening; and any clinically significant
respiratory or cardiovascular condition. Patients with
QT values at screening of ≥500 ms or QT interval
corrected using Bazett’s formula values >450 (male)
or >470 (female) ms were excluded. Patients with a
known hypersensitivity to β2-adrenergic agonists, in-
haled medication or drugs chemically related to abe-
diterol were also excluded.
Concomitant use of anticholinergic agents, short-
acting β2-agonists (except inhaled salbutamol as relief
medication), LABAs, methylxanthines, cromolyn so-
dium, nedocromil, leukotriene modifiers, non-selective
β1-blocking agents (selective β1-agents were permitted
if stable ≥4 weeks prior to screening), roflumilast or
β2-antagonists (including eye drops) was not permitted
during the study. Prohibited concomitant medications
were to be withdrawn before the patient entered the study
and discontinued prior to screening as follows: long-acting
inhaled anticholinergic agents, ≥72 h; short-acting inhaled
anticholinergic agents, ≥12 h; other oral, intranasal or
parenteral anticholinergic agents, ≥72 h; oral short-acting
β2-agonists, ≥24 h; inhaled long-acting β2-agonists, 48 h;
continuous oral or parenteral corticosteroids, ≥4 weeks;
short-term oral or parenteral corticosteroids to treat exac-
erbations, ≥6 weeks (or 3 months if exacerbation led to
hospitalisation); methylxanthines, ≥48 h; cromolyn so-
dium or nedocromil, ≥5 days; leukotriene modifiers,
≥48 h; non-selective β1 blocking agents, ≥2 weeks; any
over-the-counter medicinal product or herbal product
which could have had an effect on any efficacy or
safety assessment, ≥36 h, except paracetamol; any
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other investigational drug ≥1 month or the equivalent
of 6 half-lives of the treatment; roflumilast, ≥1 week.
Oral corticosteroids were permitted if used at stable
doses equivalent to ≤10 mg/day of prednisone. ICS
were allowed if stable ≥4 weeks prior to screening and
throughout the study (including the day of study
visits) provided dosage/regimen remained constant
during the study.
Study design and treatment
This was a randomised, double-blind, double-dummy,
placebo- and active-controlled, single-dose, six-way
crossover Phase IIa study, conducted at eight centres in
Germany, to assess the efficacy, safety and tolerability of
abediterol in patients with moderate to severe COPD.
The PK of abediterol was also assessed in a subset of
patients.
After a 14-day run-in period to assess clinical stability,
patients were assigned to one of six treatment sequences
according to a William’s design for crossover studies and
using a balanced 1:1:1:1:1:1 randomisation ratio. Each
treatment visit lasted 36 h and was separated by a 7- to
14-day washout period. A follow-up assessment was per-
formed 14 days after the final treatment period (Fig. 1).
On the first morning of each treatment visit, patients re-
ceived a single dose of abediterol (0.625, 2.5, 5 or 10 μg),
indacaterol 150 μg (active comparator) or placebo. Ad-
ministration of abediterol took place at 09:00 ± 1:00 h
each morning by inhalation from the Genuair® device,
while indacaterol was administered by inhalation from
the Onbrez® Breezhaler®. To ensure blinding, placebo
could be delivered via either device. At each visit, pa-
tients used both devices (always Genuair® first) with one
or both delivering placebo. The external appearances of
both active and placebo abediterol devices (Genuair®)
were identical, the only difference between them was the
active ingredient. With indacaterol, however, there were
minor differences in the appearance of the capsules
compared with those of placebo. Therefore, in order to
ensure blinding of indacaterol was maintained for both
patients and investigators, independent personnel at
each centre were responsible for placing the capsule in
the chamber of the Breezhaler® device prior to dosing.
The study complied with the declaration of Helsinki and
the International Conference on Harmonisation and Good
Clinical Practice guidelines. The protocol was approved by
an independent ethics committee (Ethikkommission der,
Landesärztekammer Hessen, Im Vogelsgesang 3, 60488
Frankfurt am Main). All patients provided written
informed consent.
Efficacy assessments
All efficacy endpoints are reported for the intent-to-treat
(ITT) population, defined as all randomised patients
who received ≥1 dose of abediterol and had FEV1 values
for baseline and ≥1 post-dose treatment period.
The primary efficacy variable was the change from
baseline in trough FEV1 on Day 2 (23–24 h post-dose
on Day 1). Key secondary efficacy variables included:
change from baseline in trough FVC at Day 2; change
from baseline in normalised FEV1 and FVC area
under the curve (AUC) for 0–12, 12–24 and 0–24 h
post-dose; change from baseline and absolute values
for FEV1, FVC and IC at all time points; peak and
time to peak FEV1 and FVC (maximum value ob-
served post-dose) on Day 1. Normalised AUC values
were calculated using the trapezoidal method, dividing
the pulmonary function value by the corresponding
time intervals. Bronchial reversibility was assessed
10–15 mins post-administration of 4 × 100 μg puffs of
salbutamol and was defined as ≥12 % and ≥200 mL
change from pre-test FEV1. All measures of pul-
monary function were obtained using spirometers
provided by eResearch Technology (ERT) GmbH
(Estenfeld, Germany) and met American Thoracic So-
ciety and European Respiratory Society recommenda-
tions for accuracy and precision. IC was calculated as
the highest value of three acceptable readings at each
scheduled time point. Spirometry data were manually
reviewed throughout the study by an independent,
blinded, spirometric expert from a centralised spirom-
etry company (ERTcare GmbH).
Pharmacokinetics
The PK sub-study was performed on the per-protocol
population, defined as a subset of the ITT population
who had not presented serious deviations from the
7–14 days 7–14 days 7–14 days 7–14 days 7–14 days14 (±2) days 14 (±2) days
36 h36 h36 h36 h36 h36 h





































Fig. 1 Study design
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protocol that may have affected efficacy (e.g., met all in-
clusion/exclusion criteria liable to affect the efficacy as-
sessment). PK parameters were determined for each
dose of abediterol from plasma samples collected up to
24 h post-dose in a subset of 20 patients. Abediterol
plasma levels were determined using a validated liquid
chromatography with tandem mass spectrometry assay
with a lower limit of quantification of 0.05 pg/mL. Con-
centrations of abediterol in human plasma were evalu-
ated using a non-compartmental approach by least
squares (LS) linear regression analysis of the terminal
phase of the semilogarithmic concentration-time curve.
PK parameters were calculated according to standard
methods using Kinetica software, version 4.2 (Thermo
Scientific, USA). The following PK parameters were cal-
culated: maximum plasma concentration (Cmax), time to
reach maximum plasma concentration (tmax), terminal
elimination half-life (t1/2), area under the plasma
concentration-time curve from zero to the last quantifi-
able time point (AUC0-t), area under the plasma
concentration-time curve from zero to infinity (AUC0-
∞), total body clearance from plasma (CL/f ) and appar-
ent volume of distribution (Vz/f ).
Safety and tolerability assessments
The safety population comprised all patients who re-
ceived ≥1 dose of the study drug. Adverse events
(AEs) were monitored and recorded throughout the
study. Blood pressure, 12-lead electrocardiograms
(ECG) and clinical laboratory tests (standard haema-
tology, blood chemistry, urinalysis [dipstick], blood
glucose and serum potassium) were recorded at
screening and/or pre-dose and at multiple time points
post-administration up to 36 h.
Statistical methods
Planned enrolment was 60 patients. Allowing for a 15 %
dropout rate (48 patients were planned to complete
treatment), the study had 80 % power (two-sided test at
0.05 level) to detect a difference of 100 mL between ac-
tive treatment and placebo for the primary efficacy vari-
able assuming a standard deviation for within-patient
differences of 240 mL.
Demographic and baseline characteristics were de-
scribed for the safety population using descriptive statis-
tics. Efficacy variables were analysed using an analysis of
covariance (ANCOVA) model for crossover designs.
Fixed-effect factors were sequence, treatment and
period, the random effect was patient within sequence,
and baseline FEV1 was a covariate. The patient effect
was assumed to be random and therefore the covariance
structure from the set of measurements from one pa-
tient was the compound symmetry. Between-treatment
comparisons were conducted by means of contrasts on
the treatment factor. LS means methodology was used
to estimate differences between treatments. Two-sided
hypothesis tests with a significance level of 0.05 were
used for all statistical comparisons of active treatments
versus placebo. As this was an exploratory study, the
Type I error rate was not adjusted for multiple treat-
ment comparisons.
The analysis of dose proportionality for AUC0-t
and Cmax parameters was performed by means of a
fixed-effect model, which was carried out in an
exploratory manner. Data were analysed using Statistical




Of 87 patients who underwent screening, 70 were ran-
domised (44 male, 26 female) to treatment and included
in the ITT and safety populations, and 63 completed the
study (Fig. 2). Discontinuations were due to AEs (n = 3)
or stability criteria not being met (n = 4). Demographic
and baseline characteristics data are summarised in
Table 1. Patients were 42–79 years old (mean 61.2 years),
with a mean smoking history of 48.96 pack-years; 58.6 %
(41/70) were current smokers. Overall, 70 % (49/70) of
patients had GOLD Stage II (moderate) disease and
30 % (21/70) had GOLD Stage III (severe) COPD. Mean
post-bronchodilator FEV1 was 1.72 L (58.03 % of pre-
dicted FEV1). Approximately 95 % of patients used con-
comitant medication during the study: 31.3–35.3 % used
a concomitant ICS (budesonide, 17.9–20.6 % and flutica-
sone propionate, 13.4–15.2 %) and 81.8–83.8 % used in-
haled salbutamol. Other common drug classes included
antithrombotic agents (22.1–22.7 %) and angiotensin-
converting enzyme inhibitors (19.1–21.2 %).
Screened
Randomised Discontinued study n = 4 (5.7 %)
Adverse event n = 3 (4.3 %)





n = 63 (90 %)
n = 63 (90 %)
Fig. 2 Patient disposition
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Efficacy
Primary efficacy variable
All doses of abediterol showed significant improvements
from baseline in mean trough FEV1 23–24 h post-dose
compared with placebo. LS mean differences were 0.102,
0.203, 0.233 and 0.259 L for abediterol 0.625, 2.5, 5 and
10 μg, respectively, and 0.111 L for indacaterol 150 μg
(all p < 0.0001; Fig. 3). Additionally, abediterol 2.5, 5 and
10 μg achieved significantly greater improvements from
baseline in trough FEV1 compared with indacaterol
150 μg (LS mean differences 0.092, 0.122 and 0.148 L
for 2.5, 5 and 10 μg abediterol, respectively; p < 0.0001),
while abediterol 0.625 μg was broadly equivalent to inda-
caterol 150 μg (Fig. 3).
Secondary efficacy variables
Increases from baseline in mean FEV1 occurred with all
doses of abediterol compared with placebo at all time
points on Days 1 and 2 (p < 0.05) and from 15 or
30 min post-dose compared with indacaterol (Fig. 4a–c).
The median time to peak FEV1 was 3–4 h post-
administration for all doses of abediterol and 3 h for inda-
caterol; however, peak FEV1 was of greater magnitude
with abediterol 2.5, 5 and 10 μg than with indacaterol (LS





Age (years), mean (SD) 61.2 (7.7) 62.0 56.0 66.0
BMI (kg/m2), mean (SD) 27.35 (4.20) 27.21 24.25 30.12
Gender (male), n (%) 44 (62.86)
Race (Caucasian), n (%) 69 (98.57)
Current smoker, n (%) 41 (58.57)
Smoking history (pack-years), mean (SD) 48.96 (27.98) 41.25 31.00 61.20
Severity of airflow limitation, n (%)
Moderate (GOLD Stage II) 49 (70.0)
Severe (GOLD Stage III) 21 (30.0)
Post-bronchodilator FEV1 (L)
Mean (SD) 1.72 (0.57) 1.71 1.20 2.04
% predicted, mean (SD) 58.03 (12.57) 57.95 49.20 68.90
Post-bronchodilator FVC (L)
Mean (SD) 3.57 (0.99) 3.52 2.76 4.23
% predicted, mean (SD) 97.64 (16.62) 98.70 86.50 107.80
FEV1/FVC ratio (%), mean (SD) 48.53 (10.28) 48.10 40.50 56.30
Bronchial reversibility (%), mean (SD)a 15.74 (13.25) 13.25 6.90 20.20






SABA + SAMA 4 (5.71)
Xanthines 4 (5.71)
SAMA 2 (2.86)
Influenza vaccine 1 (1.43)
Oxygen 1 (1.43)
aBronchial reversibility was assessed using salbutamol 100 μg per puff and was defined as ≥12 % and ≥200 mL change from pre-test FEV1.’ BMI body mass index,
COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, GOLD Global initiative for chronic Obstructive Lung
Disease, ICS inhaled corticosteroid, LABA long-acting β2-agonist, LAMA long-acting muscarinic antagonist, SABA short-acting β2-agonist, SAMA short-acting
muscarinic antagonist, SD standard deviation
bPrior medication defined as any medication within 15 days prior to the date of informed consent and up to the first investigational medicinal
product administration
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mean treatment difference of 0.089, 0.091 and 0.119 L, re-
spectively; p < 0.0001). Improvements in FEV1 AUC0-12,
AUC12-24 and AUC0-24 were observed with abediterol
compared with placebo (p < 0.0001, all doses) and indaca-
terol (p < 0.0001, all doses ≥2.5 μg; Table 2). Furthermore,
clinically meaningful increases from baseline in mean
FEV1 occurred with all doses of abediterol compared with
placebo at all time points on Days 1 and 2 (p < 0.05), and
from 15 or 30 min post-dose versus indacaterol 150 μg for
the 2.5, 5 and 10 μg dose levels. Changes from baseline in
trough FVC at Day 2 were also greater with abediterol
compared with placebo (LS mean differences of 0.146,
0.259, 0.294 and 0.333 L for 0.625, 2.5, 5 and 10 μg
abediterol, respectively; p ≤ 0.0002) and compared with
indacaterol (LS mean differences 0.092 L [p = 0.0176],
0.129 L [p = 0.0009] and 0.166 L [p < 0.0001] for abedi-
terol 2.5, 5 and 10 μg, respectively). In addition, im-
provements in FVC AUC0–12, AUC12–24 and AUC0–24
were recorded for all doses of abediterol compared
with placebo (p < 0.0001) and for abediterol 2.5, 5 and
10 μg compared with indacaterol (p ≤ 0.033; Table 3).
Similarly, improvements in change from baseline in IC
versus placebo and indacaterol 150 μg were recorded
with all doses of abediterol at 4 and 24 h post-
administration (4 h, p ≤ 0.0001; 24 h, p ≤ 0.0004 vs pla-
cebo; p ≤ 0.0054 at both 4 and 24 h vs indacaterol;
Fig. 5).
Pharmacokinetics
Abediterol was associated with very low systemic expos-
ure and was quantifiable in the 24-hour profile for all
doses (with the exception of the 12- and 24-hour time
points for eight of 19 patients at the 0.625 μg dose).
Tmax occurred 0.5–1.5 h post-dose, with similar values
across all doses (Fig. 6, Table 4). Mean elimination half-
life values ranged between 15 and 27.5 h across doses.
There were no relevant trends in the estimated half-
lives, total body clearance from plasma or apparent vol-
ume of distribution during the terminal phase within the
administered doses, overall suggesting a linear pharma-
cokinetic behaviour of abediterol. AUC(0-t) and Cmax
values for abediterol increased proportionally to the ad-
ministered dose within the dose range of 0.625–10 μg.
Safety and tolerability
All 70 patients received ≥1 dose of the study drug and
were included in the safety analysis. Overall, abediterol
was well tolerated and had a good safety profile. Thirty-
two patients reported 57 treatment-emergent AEs
(TEAEs): 37 were considered mild, 17 moderate and
three severe (one event of COPD exacerbation following
abediterol 5 μg and one event each of dizziness and
vomiting in the same patient following abediterol 10 μg).
Similar numbers of TEAEs occurred with each regimen,
including placebo (Table 5). The most frequently re-
ported TEAEs were nasopharyngitis (15 cases in 14 pa-
tients) and headache (eight cases in seven patients).
Treatment-related TEAEs occurred in ≤3 % of patients
for each dose and were similar to controls. No clinically
meaningful dose-response relationship was observed for
any safety outcomes. No deaths occurred during the
study. Three patients discontinued due to TEAEs, one
each following administration of abediterol 0.625 μg




























































Fig. 3 Change from baseline in trough FEV1 at Day 2 (per-protocol population). ****p < 0.0001 vs placebo;
††††p < 0.0001 vs indacaterol. Data
reported as LS mean difference from placebo (ANCOVA) ± SE. ANCOVA, analysis of covariance; FEV1, forced expiratory volume in 1 s; LS, least
squares; SE, standard error
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and indacaterol 150 μg (dyspnoea). No clinically relevant
changes in blood pressure, 12-lead ECG or clinical la-
boratory tests were observed in any treatment group
during the course of the study.
Discussion
Several Phase II clinical studies of the efficacy and safety
of abediterol have been performed in patients with
asthma [10–12, 14], however this was the first study to
investigate this novel LABA in patients with COPD. The
results demonstrate that single doses of abediterol 0.625,
2.5, 5 or 10 μg achieved a significant bronchodilatory re-
sponse compared with placebo and were safe and well
tolerated in patients with moderate to severe COPD.
Compared with placebo, all doses of abediterol re-
sulted in clinically meaningful and significantly greater
increases from baseline in peak and trough FEV1 and
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Fig. 4 a Change from baseline in FEV1 over time. Data reported as LS mean ± SE; p< 0.05 abediterol (all doses) vs placebo, all time points; p< 0.05
abediterol 2.5–10 μg vs indacaterol, all time points from 0.5 h post-dose. b Placebo-subtracted change from baseline in FEV1 AUC0–24. c Placebo-subtracted
change from baseline in peak FEV1 (per-protocol population). a p < 0.05 abediterol (all doses) vs placebo, all time points; p < 0.05 abediterol
2.5–10 μg vs indacaterol, all time points from 0.5 h post-dose. Data reported as LS means with 95 % CIs (ANCOVA). b ****p < 0.0001 vs placebo;
††††p < 0.0001 vs indacaterol. Data reported as LS mean difference from placebo (ANCOVA) ± SE. c ****p < 0.0001 vs placebo, ††††p < 0.0001 vs
indacaterol. Data reported as LS mean difference from placebo (ANCOVA) ± SE. ANCOVA, analysis of covariance; AUC0-24/24, area under the curve over
the 24 h period immediately after morning IMP administration; CI, confidence interval; FEV1, forced expiratory volume in 1 s; IMP, investigational
medicinal product; LS, least squares; SE, standard error
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Table 2 LS mean differences in changes from baseline in peak FEV1 and FEV1 AUC outcomes (ITT population)
FEV1 variable (L) Comparison Abediterol 0.625 μg (N = 67) Abediterol 2.5 μg (N = 66) Abediterol 5 μg (N = 66) Abediterol 10 μg (N = 67)
LS mean 95 % CI p-value LS mean 95 % CI p-value LS mean 95 % CI p-value LS mean 95 % CI p-value
Normalised AUC0-12 at Day 1 vs placebo 0.164 0.134, 0.195 <0.0001 0.246 0.216, 0.277 <0.0001 0.255 0.224, 0.285 <0.0001 0.283 0.252, 0.313 <0.0001
vs indacaterol 0.027 −0.004, 0.057 0.0826 0.109 0.079, 0.139 <0.0001 0.117 0.087, 0.148 <0.0001 0.145 0.115, 0.176 <0.0001
Normalised AUC12-24 at Day 1 vs placebo 0.131 0.095, 0.167 <0.0001 0.227 0.192, 0.263 <0.0001 0.264 0.228, 0.299 <0.0001 0.290 0.254, 0.326 <0.0001
vs indacaterol −0.002 −0.038, 0.035 0.9296 0.095 0.058, 0.131 <0.0001 0.131 0.095, 0.167 <0.0001 0.157 0.121, 0.193 <0.0001
Normalised AUC0-24 at Day 1 vs placebo 0.148 0.118, 0.179 <0.0001 0.237 0.206, 0.268 <0.0001 0.260 0.229, 0.291 <0.0001 0.286 0.255, 0.317 <0.0001
vs indacaterol 0.014 −0.017, 0.045 0.3799 0.102 0.071, 0.134 <0.0001 0.125 0.094, 0.157 <0.0001 0.152 0.120, 0.183 <0.0001
Peak FEV1 at Day 1 vs placebo 0.185 0.147, 0.223 <0.0001 0.255 0.217, 0.292 <0.0001 0.257 0.219, 0.295 <0.0001 0.285 0.247, 0.323 <0.0001
vs indacaterol 0.019 −0.019, 0.057 0.3350 0.089 0.050, 0.127 <0.0001 0.091 0.053, 0.129 <0.0001 0.119 0.081, 0.157 <0.0001
Analyses were performed on the ITT population. For both placebo and indacaterol, N = 68
LS mean differences and p-values obtained from an ANCOVA model for crossover designs with change from baseline in FEV1 variable as response, sequence, treatment group and period as fixed effect factors, patient
within sequence as a random effect and the corresponding baseline value at each period as a covariate
ANCOVA, analysis of covariance; AUC0-12 area under the curve over the 12 h period immediately after morning IMP administration, AUC12-24 area under the curve over the 12 h nighttime period after morning IMP
administration, AUC0-24 area under the curve over the 24 h period immediately after morning IMP administration, FEV1 forced expiratory volume in 1 s, IMP investigational medicinal product, ITT intent-to-treat, LS least














Table 3 Peak FVC and FVC AUC outcomes (safety population)
FVC variable (L) Comparison LS mean differences in changes from baseline
Abediterol 0.625 μg (N = 67) Abediterol 2.5 μg (N = 66) Abediterol 5 μg (N = 66) Abediterol 10 μg (N = 67)
LS mean 95 % CI p- value LS mean 95 % CI p-value LS mean 95 % CI p-value LS mean 95 % CI p-value
Normalised AUC0-12 at Day 1 vs placebo 0.227 0.169, 0.284 <0.0001 0.280 0.222, 0.337 <0.0001 0.301 0.243, 0.358 <0.0001 0.347 0.289, 0.405 <0.0001
vs indacaterol 0.010 −0.047, 0.068 0.7258 0.063 0.05, 0.121 0.0323 0.084 0.027, 0.142 0.0044 0.130 0.072, 0.188 <0.0001
Normalised AUC12-24 at Day 1 vs placebo 0.182 0.114, 0.249 <0.0001 0.308 0.201, 0.376 <0.0001 0.352 0.285, 0.420 <0.0001 0.386 0.319, 0.454 <0.0001
vs indacaterol −0.026 −0.094, 0.042 0.4471 0.100 0.031, 0.166 0.0045 0.144 0.076, 0.212 <0.0001 0.178 0.110, 0.247 <0.0001
Normalised AUC0-24 at Day 1 vs placebo 0.208 0.153, 0.263 <0.0001 0.294 0.239, 0.349 <0.0001 0.332 0.276, 0.387 <0.0001 0.369 0.313, 0.424 <0.0001
vs indacaterol −0.007 −0.063, 0.048 0.7996 0.079 0.023, 0.135 0.0058 0.117 0.061, 0.172 <0.0001 0.154 0.098, 0.209 <0.0001
Peak FVC at Day 1 vs placebo 0.152 0.035, 0.270 0.0110 0.191 0.074, 0.309 0.0015 0.201 0.083, 0.318 0.0009 0.244 0.127, 0.361 <0.0001
vs indacaterol 0.013 −0.104, 0.131 0.8219 0.052 −0.065, 0.170 0.3829 0.062 −0.056, 0.179 0.3024 0.105 −0.012, 0.222 0.0795
Analyses were performed on the ITT population. For both placebo and indacaterol, N = 68
LS mean differences and p-values obtained from an ANCOVA model for crossover designs with change from baseline in FVC variable as response, sequence, treatment group and period as fixed effect factors, patient
within sequence as a random effect and the corresponding baseline value at each period as a covariate
ANCOVA, analysis of covariance; AUC0-12 area under the curve over the 12 h period immediately after morning IMP administration, AUC12-24 area under the curve over the 12 h nighttime period immediately after
morning IMP administration, AUC0-24 area under the curve over the 24 h period immediately after morning IMP administration, CI confidence interval, FVC forced vital capacity, IMP investigational medicinal product,














of abediterol. All doses of abediterol produced a change
in trough FEV1 that exceeded the minimum clinically
important difference of 100 mL versus placebo [25].
Similarly, abediterol produced dose-related improve-
ments in IC versus placebo, suggesting that abediterol
reduces lung hyperinflation. Taken together, these results
suggest that abediterol is likely to be effective for the
treatment of COPD and has a clear once-daily dosing
profile.
Furthermore, abediterol 2.5, 5 and 10 μg achieved sig-
nificantly greater improvements in bronchodilatory re-
sponse compared with indacaterol 150 μg, starting from
30 min post-dose for the 2.5 μg dose and from 15 min

























































































Fig. 5 Change from baseline in inspiratory capacity versus placebo and indacaterol (ITT population). Data reported as LS mean difference ± 95 % CI.
***p < 0.001 vs placebo; †p < 0.05 vs indacaterol; ††p < 0.01 vs indacaterol. CI, confidence interval; LS, least squares
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results are consistent with pre-clinical studies, which
have shown that abediterol displays greater affinity for
β2-adrenoceptors and a higher functional selectivity for
β2-adrenoceptors over β1-adrenoceptors than indacaterol
in a cellular model of overexpressed human receptors,
and greater potency than indacaterol in isolated human
bronchi [9]. Although this was only a single-dose investi-
gation and the results need to be confirmed following
repeat dosing, it could be hypothesised that the results
may translate to a reduction in dynamic hyper-inflation
which would result in an improvement in symptoms
(breathlessness), an increase in exercise tolerance and a
potential reduction in exacerbations (through raising a
patient’s exacerbation reporting-threshold) [26].
Inhaled doses of abediterol 0.625–10 μg showed a lin-
ear dose-dependent relationship for PK parameters.
High and aberrant physiological values for the total
clearance from plasma and the apparent volume of dis-
tribution were observed, suggesting a very low bioavail-
ability of abediterol. Plasma exposure obtained after
single inhaled doses of 0.625–10 μg of abediterol was
very low (sub-picogram range), thereby reducing the po-
tential for undesired systemic side effects [27]. Abedi-
terol was safe and well tolerated by patients with
moderate to severe COPD, with no evidence that the
increased bronchodilatory response compared with inda-
caterol was associated with an increase in the incidence
of AEs.
Overall, the results reported here for abediterol in pa-
tients with COPD are consistent with the efficacy results
for abediterol in patients with asthma, including studies
using different inhaler devices [10–12, 14]. Abediterol
has demonstrated good efficacy in patients with persist-
ent stable asthma, with significant improvements in
bronchodilation compared with placebo as early as
5 min post-dose [11, 12]. Studies of abediterol delivered
via the Genuair® or Cyclohaler® devices have shown that
peak FEV1 is reached 2–4 h post-dose, and clinically and
statistically significant bronchodilation is maintained
over 24 h post-dose [10–12, 14]. The results of these
studies, together with the data we report here, are com-
patible with a once-daily dosing regimen in patients with
COPD or asthma.
The statistical power calculation in this study was
based on a comparison of abediterol with placebo, re-
quiring 48 patients to complete the study to provide
80 % power to detect a treatment difference of 100 mL
in trough FEV1 at Day 2. As the protocol was not specif-
ically powered for the comparison of abediterol with
indacaterol, this could be viewed as a potential study
Table 5 TEAEs occurring in ≥2 patients in any treatment group (safety population)







0.625 μg (N = 67) 2.5 μg (N = 66) 5 μg (N = 66) 10 μg (N = 67)
Any 9 (13.2) 10 (14.7) 7 (10.4) 5 (7.6) 6 (9.1) 9 (13.4) 32 (45.7)
Nasopharyngitis 2 (2.9) 5 (7.4) 4 (6.0) 1 (1.5) 1 (1.5) 2 (3.0) 15 (21.4)
Headache 3 (4.4) 0 1 (1.5) 0 2 (3.0) 2 (3.0) 8 (11.4)
Dyspnoea 0 2 (2.9) 0 0 0 0 2 (2.9)
TEAE treatment-emergent adverse event
Table 4 Mean PK parameters of abediterol in patients with COPD
Parameter (unit) Abediterol 0.625 μg Abediterol 2.5 μg Abediterol 5 μg Abediterol 10 μg
(n = 19) (n = 19) (n = 19) (n = 20)
mean (SD) mean (SD) mean (SD) mean (SD)
Cmax (pg/mL) 0.374 0.195 1.230 0.637 2.24 0.927 5.10 2.67
tmax
a (h) 0.50 0.25–8 0.50 0.22–1.5 0.45 0.25–1.5 0.50 0.25–0.75
t½ (h) 27.5
b 9.02 17.4c 6.76 16.0d 5.04 15.1e 3.35
AUC0-t (pg.h/mL) 2.29 1.17 7.84 2.82 13.3 4.48 28.0 11.0
AUC (pg.h/mL) 5.95b 2.66 12.5c 6.01 19.7d 4.48 38.1e 14.1
CL/f (L/h) 119b 40 252c 135 268d 70.6 310e 161
Vz/f (L) 4345
b 753 5736c 2629 6219d 2675 7060e 5199
AUC0-t area under the concentration-time curve from zero to the last quantifiable time point, AUC area under the concentration-time curve, CL/f total body
clearance of drug from plasma after extravascular administration, Cmax maximum measured plasma concentration, COPD chronic obstructive pulmonary disease,
h hour(s), n number of patients with data, PK pharmacokinetic, SD standard deviation, tmax time to reach maximum concentration, t½ terminal elimination half-life,
Vz/f apparent volume of distribution during terminal phase after extravascular administration
amedian value (min-max), bn = 5, cn = 11, dn = 12, en = 9
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limitation. However, the observed treatment differences
were >100 mL for the abediterol 5 and 10 μg doses, and
92 mL for the 2.5 μg dose, and all were statistically sig-
nificant, suggesting that these doses of abediterol were
superior to indacaterol in this study.
Conclusion
Single doses of abediterol (0.625–10 μg) administered
via the Genuair® inhaler provided statistically significant
and clinically relevant improvements in bronchodilation
compared with placebo in patients with moderate to se-
vere COPD. Abediterol 2.5, 5 and 10 μg provided signifi-
cantly greater improvements in bronchodilation in these
patients over 36 h compared with indacaterol 150 μg.
Abediterol had low systemic exposure and showed a
good overall safety and tolerability profile at all doses.
The results suggest that abediterol is a promising new
once-daily LABA for the treatment of COPD.
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AE, adverse event; ANCOVA, analysis of covariance; AUC, area under the
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